Cellectis Q2 Revenue Misses Estimates Despite Better Loss
Cellectis reported a smaller-than-expected loss but revenue fell short of forecasts, prompting a sell rating from Weiss Ratings.
Cellectis S.A. (NASDAQ:CLLS) reported second-quarter results on August 7, revealing a net loss per share of $0.22. This figure beat the consensus estimate of a $0.26 loss by $0.04, indicating a slight improvement in cost management or other non-operational factors. However, the company’s top-line performance lagged significantly behind market expectations.
Revenue for the quarter stood at $6.90 million, a substantial decline from the $11.05 million projected by analysts. The disparity between actual and forecasted income highlights ongoing challenges in commercializing its gene-edited T-cell therapies. According to data from GN stocks/nasdaq, the market has reacted negatively to these figures, with the stock trading below its key moving averages.
Financial Metrics Reflect Operational Strain
The company’s financial health shows signs of pressure despite the EPS beat. Cellectis posted a negative return on equity of 94.19% and a net margin of -102.34%, indicating that the business is spending more than it generates. The price-to-earnings ratio stands at -2.82, a metric that is less useful for unprofitable firms but underscores the lack of current profitability.
Liquidity and leverage ratios suggest a manageable but tight financial structure. The current ratio is 1.37, and the quick ratio is also 1.37, meaning the company has sufficient short-term assets to cover its liabilities. However, the debt-to-equity ratio of 1.61 indicates a significant level of leverage relative to shareholder equity. The beta of 2.92 suggests the stock is nearly three times as volatile as the broader market.
Technical Breakdown and Market Position
Cellectis shares crossed below their 50-day moving average on Monday, a technical signal often interpreted as a shift in short-term momentum. The 50-day simple moving average is calculated at $3.00, while the 200-day average sits higher at $3.34. The stock traded as low as $1.75 during the session, closing at $1.83 with a volume of 1,172,743 shares.
The market capitalization has contracted to $183.62 million. Institutional investors and hedge funds hold 63.90% of the outstanding shares, indicating a high concentration of ownership among professional money managers. This level of institutional interest provides a floor for demand but also means that large block trades can have a pronounced impact on the share price.
Analyst Sentiment Remains Mixed
Wall Street views on Cellectis are divided, with recent actions reflecting caution. Weiss Ratings reiterated a
